{Reference Type}: Journal Article
{Title}: CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases.
{Author}: Chevalier K;Genin M;Jean TP;Avouac J;Flipo RM;Georgin-Lavialle S;El Mahou S;Pertuiset E;Pham T;Servettaz A;Marotte H;Domont F;Chazerain P;Devaux M;Mekinian A;Sellam J;Fautrel B;Rouzaud D;Ebstein E;Costedoat-Chalumeau N;Richez C;Hachulla E;Mariette X;Seror R;
{Journal}: Front Med (Lausanne)
{Volume}: 10
{Issue}: 0
{Year}: 2023
{Factor}: 5.058
{DOI}: 10.3389/fmed.2023.1152587
{Abstract}: <B>UNASSIGNED: </B>Autoimmune/inflammatory rheumatic diseases (AIRDs) patients might be at-risk of severe COVID-19. However, whether this is linked to the disease or to its treatment is difficult to determine. This study aimed to identify factors associated with occurrence of severe COVID-19 in AIRD patients and to evaluate whether having an AIRD was associated with increased risk of severe COVID-19 or death.<BR><B>UNASSIGNED: </B>Two databases were analyzed: the EDS (Entrepôt des Données de Santé, Clinical Data Warehouse), including all patients followed in Paris university hospitals and the French multi-center COVID-19 cohort [French rheumatic and musculoskeletal diseases (RMD)]. First, in a combined analysis we compared patients with severe and non-severe COVID-19 to identify factors associated with severity. Then, we performed a propensity matched score case-control study within the EDS database to compare AIRD cases and non-AIRD controls.<BR><B>UNASSIGNED: </B>Among 1,213 patients, 195 (16.1%) experienced severe COVID-19. In multivariate analysis, older age, interstitial lung disease (ILD), arterial hypertension, obesity, sarcoidosis, vasculitis, auto-inflammatory diseases, and treatment with corticosteroids or rituximab were associated with increased risk of severe COVID-19. Among 35,741 COVID-19 patients in EDS, 316 having AIRDs were compared to 1,264 Propensity score-matched controls. AIRD patients had a higher risk of severe COVID-19 [aOR = 1.43 (1.08-1.87), p = 0.01] but analysis restricted to rheumatoid arthritis and spondyloarthritis found no increased risk of severe COVID-19 [aOR = 1.11 (0.68-1.81)].<BR><B>UNASSIGNED: </B>In this multicenter study, we confirmed that AIRD patients treated with rituximab or corticosteroids and/or having vasculitis, auto-inflammatory disease, and sarcoidosis had increased risk of severe COVID-19. Also, AIRD patients had, overall, an increased risk of severe COVID-19 compares general population.